Poland· PL-100444538
MenQuadfi
A meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert product containing szczepionka przeciw meningokokom grup a, c, w i y, skoniugowana, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert is registered in 11 of 19 countries.
Countries holding a registration under ATC J07AH08 (meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert · ATC J07AH08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Szczepionka przeciw meningokokom grup A, C, W i Y, skoniugowana
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Poland (PL)
- ATC code
- J07AH08
- ATC class
- Meningokokken A, C, Y, W-135, tetravalent, gereinigtes Polysaccharid-Antigen, konjugiert
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 7
- gtin05909991452315
- gtin03664798066418
- gtin04150029125157
- gtin07680682210015
- gtin05909991452322
- gtin05909991494148
- gtin05909991494155
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07AH08
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert, as other registers publish it.
- CanadaMENACTRASANOFI PASTEUR LIMITED
- FinlandMenQuadfiSanofi Winthrop Industrie
- IcelandMenQuadfiSanofi Winthrop Industrie
- BelgiumMenQuadfiSanofi Winthrop Industrie
- DenmarkMenQuadfiSanofi Winthrop Industrie
- CzechiaMENQUADFISanofi Winthrop Industrie, Gentilly
- CzechiaMENQUADFISanofi Winthrop Industrie, Gentilly
- CzechiaMENQUADFISanofi Winthrop Industrie, Gentilly
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cc3ee7c0-2ccc-40db-9c7c-1714c58988c0 GET /v1/drugs/cc3ee7c0-2ccc-40db-9c7c-1714c58988c0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": null,
"packaging": "05909991452315 ¦ Rp ¦ EU/1/20/1483/001 ¦ 138615\n1 fiol. 0,5 ml\n¦ UR/Z/4c/145/24 - 03664798066418 ¦ UR/Z/4c/176/23 - 04150029125157 ¦ UR/Z/4c/077/24 - 04150029125157, 07680682210015 ¦ UR/Z/4c/223/25 - 03664798066418 ¦ UR/Z/4c/231/26 - 03664798066418\n05909991452322 ¦ Rp ¦ EU/1/20/1483/002 ¦ 138616\n5 fiol. 0,5 ml\n05909991494148 ¦ Rp ¦ EU/1/20/1483/003 ¦ 146496\n1 fiol. 0,5 ml ¦ 2 igły ¦ 1 strzyk. \n05909991494155 ¦ Rp ¦ EU/1/20/1483/004 ¦ 146497\n10 fiol. 0,5 ml",
"substance": null,
"common_name": "Szczepionka przeciw meningokokom grup A, C, W i Y, skoniugowana",
"pl_product_id": "100444538",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.